ASSIST — Atrasentan add-on cut proteinuria on RASi + SGLT2i in IgAN (2026) — Trial Summary

ASSIST — Atrasentan add-on cut proteinuria on RASi + SGLT2i in IgAN (2026): Randomized, double-blind, placebo-controlled crossover trial of atrasentan 0.75 mg once daily versus matching placebo in adults with IgA nephropathy, eGFR ≥30 mL/min/1.73 m², and urinary protein >0.5 g/d while on maximal, st

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.